{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:40:38Z","timestamp":1790775638080,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Traditional Chinese Medical Science and Technology Project of Zhejiang Province of China","award":["2017ZB032"],"award-info":[{"award-number":["2017ZB032"]}]},{"name":"Traditional Chinese Medical Science and Technology Project of Zhejiang Province of China","award":["2014ZA028"],"award-info":[{"award-number":["2014ZA028"]}]},{"name":"Medical Science and Technology Project of Zhejiang Province","award":["2017KY503"],"award-info":[{"award-number":["2017KY503"]}]},{"name":"Educational Commission of Zhejiang Province of China","award":["Y201431280"],"award-info":[{"award-number":["Y201431280"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To systematically assess the clinical efficacy and safety of leflunomide for treating psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, and Cochrane Library databases were searched until 1 January, 2018, to include relevant studies in this single\u2010arm meta\u2010analysis. Psoriasis improvement was evaluated using Psoriasis Area and Severity Index (PASI) scores. The primary outcome in patients was assessed using the Psoriatic Arthritis Response Criteria (PsARC). Other effectiveness evaluations included those of adverse events, quality of life including functional status (Health Assessment Questionnaire [HAQ] total score), and a quality\u2010of\u2010life instrument for dermatologic diseases (Dermatology Life Quality Index [DLQI] total score).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 6 studies were included. After leflunomide treatment, 48% of the patients experienced a reduction of \u226550% based on PASI scores (95% confidence interval [CI]: 0.22\u20100.73). PASI 75 improvement was observed among 25% of the patients (95% CI: 0.11\u20100.38). The primary effectiveness analysis revealed that 15% of the patients (95% CI: 0.07\u20100.26) discontinued leflunomide treatment. Further, 77% of the patients (95% CI: 0.59\u20100.92) achieved a PsARC response. Adverse events occurred in 38% of the patients (95% CI: 0.04\u20100.71). The mean\u00a0\u00b1\u00a0SD percentage PASI improvement was \u22124.88 (95% CI: \u22128.92, \u22120.85). Moreover, DLQI and HAQ were \u22122.02 (95% CI: \u22123.01, \u22121.03) and \u22120.19 (95% CI: \u22120.29, \u22120.09), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Leflunomide is an effective and well\u2010tolerated treatment for PsA, and would be a safe and convenient option.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13599","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:58:36Z","timestamp":1559005116000},"page":"1498-1505","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of leflunomide in psoriatic arthritis treatment: A single\u2010arm meta\u2010analysis"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-4278","authenticated-orcid":false,"given":"Qiaoding","family":"Dai","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou China"},{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiali","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1413351"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-016-1111-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3537-5"},{"issue":"4","key":"e_1_2_9_5_1","first-page":"603","article-title":"Effect of anti\u2010TNF and conventional synthetic disease\u2010modifying anti\u2010rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis","volume":"56","author":"Tillett W","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2016.10.005"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X16635887"},{"issue":"1","key":"e_1_2_9_8_1","first-page":"51","article-title":"Efficacy and safety of leflunomide in psoriatic arthritis","volume":"24","author":"Asaduzzaman A","year":"2014","journal-title":"J Pak Assoc Dermatol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21848"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"issue":"6","key":"e_1_2_9_13_1","first-page":"881","article-title":"Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate","volume":"25","author":"Malesci D","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"e_1_2_9_14_1","first-page":"22","article-title":"Results of leflunomide treatment of psoriatic arthritis","volume":"79","author":"Pchelintseva AO","year":"2007","journal-title":"Ter Arkh"},{"issue":"7","key":"e_1_2_9_15_1","first-page":"570","article-title":"A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis","volume":"48","author":"Zhang GL","year":"2009","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.76"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-1033-1"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3488-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1673-3"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2017.07.020"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2013.05.006"},{"issue":"1","key":"e_1_2_9_22_1","first-page":"80","article-title":"Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials","volume":"23","author":"Martin K","year":"2005","journal-title":"Clin Exp Rheumatol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13599","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13599","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13599","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T06:50:13Z","timestamp":1694328613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/1756-185X.13599"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13599","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"2018-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}